Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 463-469

  Yoshitomi, Munehiro ^a   Yutani, Shigeru ^b   Matsueda, Satoko ^b   Ioji, Tetsuya ^b   Komatsu, Nobukazu ^b   Shichijo, Shigeki ^b   Yamada, Akira ^b   Itoh, Kyogo ^b   Sasada, Tetsuro ^b   Kinoshita, Hisafumi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Biliary tract cancer; Biomarker; Peptide vaccine

Indexed keywords

CANCER VACCINE; CYPB 129; EGFR 800; EZH2 735; HNRPL 140; HNRPL 501; LCK 208; LCK 246; LCK 422; LCK 486; LCK 488; MAP 432; MRP3 1293; MRP3 503; PAP 213; PSA 248; PSMA 624; PTHRP 102; SART2 161; SART3 109; SART3 302; SART3 309; SART3 511; SART3 734; SART3 93; UBE 43; UBE 85; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHSC2 103; WHSC2 141;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIGEN SPECIFIC IMMUNITY; ARTICLE; ASCITES; BILIARY TRACT CANCER; BLOOD TOXICITY; CHOLANGITIS; CLINICAL ARTICLE; CONSTIPATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STRICTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMORAL IMMUNITY; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNITY; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NUTRITIONAL STATUS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PERSONALIZED PEPTIDE VACCINATION; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SIDE EFFECT; T LYMPHOCYTE; VACCINATION;

EID: 84855858099     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.424     Document Type: Article

References (25)

1. Yachimski P and Pratt DS: Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. JClin Gastroenterol 42: 178-190, 2008.
2. Hezel AF, Deshpande V and Zhu AX: Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28: 3531-3540, 2010.
3. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
4. Gruenberger B, Schueller J, Heubrandtner U, et al: Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11: 1142-1148, 2010.
5. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M and Itoh K: Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 46: 1514-1519, 2010.
6. Mine T, Sato Y, Noguchi M, et al: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937, 2004.
7. Itoh K and Yamada A: Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97: 970-976, 2006.
8. Yanagimoto H, Shiomi H, Satoi S, et al: A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24: 795-801, 2010.
9. Sato Y, Fujiwara T, Mine T, et al: Immunological evaluation of personalized peptide vaccination in combination with a 5-fluo-rouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 98: 1113-1119, 2007.
10. Hattori T, Mine T, Komatsu N, et al: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 58: 1843-1852, 2009.
11. Noguchi M, Kakuma T, Uemura H, et al: A randomized phaseII trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother59: 1001-1009, 2010.
12. Terasaki M, Shibui S, Narita Y, et al: Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen - A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29: 337-344, 2011.
13. Komatsu N, Shichijo S, Nakagawa M and Itoh K: New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64: 535-545, 2004.
14. Noguchi M, Mine T, Komatsu N, et al: Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10: 1266-1279, 2011.
15. Disis ML: Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother60: 433-442, 2011.
16. Butterfield LH, Palucka AK, Britten CM, et al: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17: 3064-3076, 2011.
17. Hoos A, Eggermont AM, Janetzki S, et al: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102: 1388-1397, 2010.
18. Naugler WE and Karin M: The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14: 109-119, 2008.
19. Scambia G, Testa U, Benedetti Panici P, et al: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354-356, 1995.
20. Nakashima J, Tachibana M, Horiguchi Y, et al: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706, 2000.
21. Okada S, Okusaka T, Ishii H, et al: Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol28: 12-15, 1998.
22. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT and Carty SE: Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 227: 398-404, 1998.
23. Marigo I, Bosio E, Solito S, et al: Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32: 790-802, 2010.
24. Lechner MG, Liebertz DJ and Epstein AL: Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185: 2273-2284, 2010.
25. Zou W and Restifo NP: T(H)17 cells In tumour immunity and immunotherapy. Nat Rev Immunol 10: 248-256, 2010.